The extent of near-surface permafrost, or perennially frozen ground within 3 m of the surface, was estimated for the Mackenzie River delta by determining its association with riparian vegetation communities in the field, and by subsequently mapping these vegetation communities using SPOT-5 data and the supervised maximum-likelihood classification technique. Near-surface permafrost was absent beneath willow-horsetail (Salix-Equisetum) vegetation communities on point bars and alluvial islands throughout the delta and beneath horsetail (Equisetum) communities in the southern and central delta. Near-surface permafrost was found beneath all other vegetation communities and land surface types. Multispectral SPOT-5 data were classified with overall accuracies greater than 80 per cent. Using the remotely sensed vegetation community data, near-surface permafrost was estimated to occur beneath 93 per cent, 95 per cent and 96 per cent of the land surface within the investigation areas of the southern, central and northern delta, respectively. In contrast to the most recent Permafrost Map of Canada, these results indicate that the Mackenzie Delta is part of the continuous permafrost zone. Figure 3 Vegetation communities in the delta: (a) horsetail; (b) willow-horsetail; (c) alder; (d) spruce; (e) sedge; and (f) Salix richardsonii. Spruce forests are absent in the northern delta.

Cytopenia after high-dose chemotherapy and autologous stem cell reinfusion is a major cause of morbidity. Ex vivo cultured expansion and differentiation of CD34+ peripheral blood progenitor cells (PBPC) to neutrophil precursors may shorten the neutropenic period further. We explored the use of these ex vivo cultured PBPCs in nine patients with metastatic breast cancer. All underwent PBPC mobilization with cyclophosphamide, VP-16, and G-CSF. Subsequently, they underwent four to five apheresis procedures. One apheresis product from each patient was prepared using the Isolex 300 Magnetic Cell Separation System (Baxter Immunotherapy, Irvine, CA) to obtain CD34+ cells. These cells were then cultured in gas permeable bags containing serum-free X-VIVO 10 (BioWhittaker, Walkersville, MD) medium supplemented with 1% human serum albumin and 100 ng/mL PIXY321. At day 12 of culture the mean fold expansion was 26x with a range of 6 to 64x. One patient's cells did not expand because of a technical difficulty. The final cell product contained an average of 29.3% CD15+ neutrophil precursors with a range of 18.5% to 48.1%. The patients underwent high-dose chemotherapy with cyclophosphamide, carboplatin, and thiotepa. On day 0, the cryopreserved PBPCs were reinfused and on day +1 the 12-day cultured cells were washed, resuspended, and reinfused into eight of nine patients. One patient was not infused with cultured cells. The mean number of cultured cells reinfused was 44.6 x 10(6) cells/kg with a range of 0.8 to 156.6 x 10(6) cells/kg. No toxicity was observed after reinfusion. The eight patients have recovered absolute neutrophil counts > 500/microL on a median of 8 days (range 8 to 10 days); the median platelet transfusion independence occurred on day 10 (range 8 to 12 days) and platelet counts > 50,000/microL were achieved by day 12 (range 9 to 14) for the seven patients whose platelet counts could be determined. Expanded CD34+ selected PBPC can be obtained and safely reinfused into patients.

No abstract

No abstract